FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine. What is described is a pharmaceutical composition of a medicinal agent of sedative and spasmolytic action in the form of soft gelatine capsules, containing alpha-bromoisovaleric acid ethyl ester and menthol solution in menthyl isovalerate in the following ratio, wt %: alpha-bromoisovaleric acid ethyl ester 2.0-6.0; menthol solution in menthyl isovalerate 31.0-81.2; addition agents - the rest. The addition agent is a substance specified among: fatty component, glycine, taurine, fatty component with glycine, fatty component with taurine, fatty component with glycine and taurine, whereas the fatty component is peppermint oil, olive oil, hop oil, corn oil or any combination of the above substances.
EFFECT: providing the combined pharmacological sedative, spasmolytic, depressant, vasorelaxant and analgesic action, improving cardiological action of the agent, achieving high dosage accuracy of the active substances and fast release thereof when in use.
2 cl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINE OF SEDATIVE AND ANTISPASMODIC EFFECT AND METHOD OF PREPARATION (VERSIONS) | 2005 |
|
RU2349334C2 |
| SEDATIVE AND SPASMOLITHIC MEANS AND METHOD FOR ITS PRODUCTION | 2015 |
|
RU2633064C2 |
| METHOD OF OBTAINING A SOLID FORM OF THE DRUG SEDATIVE AND ANTISPASMODIC ACTION | 2015 |
|
RU2578432C9 |
| SEDATIVE AND MUSCLE RELAXANT ACTION DRUG | 2019 |
|
RU2719376C1 |
| COMPOSITION AND METHOD OF PRODUCING MEDICINE | 2017 |
|
RU2675627C1 |
| SEDATIVE AND SPASMOLYTIC AGENT | 2014 |
|
RU2535019C1 |
| SOLID DOSAGE FORM OF PREPARATION OF SEDATIVE AND HYPNOTIC EFFECT | 2013 |
|
RU2589833C2 |
| SOLID DRUG FORM OF MEDICATION WITH SEDATIVE AND ANTISPASMODIC EFFECT | 2013 |
|
RU2570374C2 |
| SEDATIVE DRUG AND METHOD OF MARJORAM ESSENTIAL OIL PREPARING FOR MEDICINAL AIMS | 2000 |
|
RU2157224C1 |
| LIQUID SEDATIVE | 2021 |
|
RU2779256C1 |
